Innate Pharma strengthens its platform in the pharmacology of Toll-like-receptors (TLR) with assets licensed from US-based global pharmaceutical company Schering-Plough Corporation and advanced R&D collaboration with "Institut de cancérologie Gustave-Roussy", France's largest cancer center.
| PR in english | 89.46 KB |
| CP en français | 91.73 KB |